An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk
Figures

Volcano plot of all findings from main and validation cohort.
Volcano plot depicting spread of p-values of significant and non-significant ABO and RhD blood groups for main cohort and validated results (live version available as online Supplementary file 1). The labels represent the nine findings with the lowest p-value in the validation cohort.

Manhattan plot of all findings from main and validation cohort mapped by ICD chapter.
Manhattan plot depicting distribution of p-values for significant and non-significant associations between ABO and RhD blood groups and available outcomes for main cohort and validated results mapped by disease chapter in ICD (live version available as online Supplementary file 2).

All significant un-adjusted findings from the validation cohort.
Significant disease categories in the validation cohort. Blood group as compared to blood group O and log10(IRR) displayed with 95% confidence bands. All p-values are raw, highlighted p-value indicates associations that remained statistically significant also after Bonferroni adjustment.

ABO blood group.
QQ plot for p-values in exploratory cohort in ABO analysis.
Tables
Baseline characteristics of main and validation cohort.
Main cohort | Validation cohort | |||
---|---|---|---|---|
Number | 4,204,234 | 1,197,522 | ||
Age, median (IQR) | ||||
Age, median (IQR) | 52 | (30-71) | 30 | (23-41) |
Year of birth, median (IQR) | 1949 | (1931–1971) | 1966 | (1953–1978) |
Sex, % | 60 | 49 | ||
Blood group, % | ||||
A | 47 | 45 | ||
AB | 5 | 5 | ||
B | 10 | 11 | ||
O | 38 | 39 | ||
RhD positive, % | 84 | 82 |
-
IQR, interquartile range.
Meta-summary of results.
Main cohort | Validation cohort | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Individuals | 4,204,234 | 1,197,522 | |||||||||
Person-years, sum | 50 M | 22 M | |||||||||
Events, median (IQR) | 4748 (869–23,166) | 7129 (2464–19,973) | |||||||||
A | AB | B | ABO total | RhD positive | A | AB | B | ABO total | RhD positive | ||
Before adjustment | 229 | 129 | 179 | 537 | 106 | 64 | 37 | 42 | 143 | 5 | |
Positive effects, N | 150 | 79 | 107 | 336 | 61 | 47 | 23 | 22 | 92 | 3 | |
Negative effects, N | 79 | 50 | 72 | 201 | 45 | 17 | 14 | 20 | 51 | 2 | |
After adjustment* | 108 | 56 | 70 | 234 | 13 | 26 | 13 | 10 | 49 | 1 | |
Positive effects, N | 66 | 38 | 36 | 140 | 10 | 19 | 10 | 6 | 35 | 1 | |
Negative effects, N | 42 | 18 | 34 | 94 | 3 | 7 | 3 | 4 | 14 | 0 | |
Positive IRR, median (range) | 1.05 (1.01–1.72) | 1.09 (1.03–1.52) | 1.09 (1.02–1.39) | 1.05 (1.02–1.08) | 1.1 (1.03–1.57) | 1.32 (1.07–1.89) | 1.5 (1.07–1.64) | 1.12 (1.12–1.12) | |||
Negative IRR, median (range) | 0.95 (0.77–0.99) | 0.92 (0.74–0.97) | 0.92 (0.57–0.98) | 0.97 (0.9–0.97) | 0.92 (0.86–0.95) | 0.84 (0.81–0.87) | 0.88 (0.83–0.93) | - |
-
*In the main and validation cohort FDR and Bonferroni adjustment was conducted, respectively.
Additional files
-
Supplementary file 1
Interactive Volcano plot depicting spread of p-values of significance and non-significance.
ABO and RhD blood groups for main cohort and validated results. Labels are displayed on hoovering with information on blood group, disease category, p-value (FDR-adjusted and raw p-value depending on analysis, IRR with 95% confidence interval), events, and person-time.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp1-v2.zip
-
Supplementary file 2
Manhattan plot depicting distribution of p-values for significant and non-significant associations between ABO and RhD blood groups and available outcomes for main cohort and validated results mapped by disease chapter in ICD.
Labels are displayed on hoovering with information on blood group, disease category, p-value (FDR-adjusted and raw p-value depending on analysis, IRR with 95% confidence interval), events, and person-time.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp2-v2.zip
-
Supplementary file 3
Non-cancer disease categories with ICD codes and names of categories, searchable html-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp3-v2.zip
-
Supplementary file 4
Cancer disease categories, searchable html-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp4-v2.zip
-
Supplementary file 5
All significant results from ABO analysis in the main cohort after FDR adjustment, searchable html-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp5-v2.zip
-
Supplementary file 6
All significant results from RhD analysis in the main cohort after FDR adjustment, searchable html-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp6-v2.zip
-
Supplementary file 7
All findings with p-value less than 0.05 in the validation cohort in the ABO analysis, Bonferroni robust findings labeled, searchable html-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp7-v2.zip
-
Supplementary file 8
All findings with p-value less than 0.05 in the validation cohort in the RhD analysis, Bonferroni robust findings labeled, searchable html-file and excel-file.
- https://cdn.elifesciences.org/articles/65658/elife-65658-supp8-v2.zip
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/65658/elife-65658-transrepform-v2.pdf